Wedbush maintains Beam Therapeutics at Outperform, raises price target to $33 from $30
Wedbush reaffirmed its Outperform rating for Beam Therapeutics and increased its price target to $33 from $30, suggesting a 31.2% upside from the Nov 10 close of $25.15. Recent analyst price targets for the company range from $30 to $80.

